Print View Attached Docs:
80915:NEUROMYELITIS OPTICA (NMO) AUTOANTIBODY, IgG, SERUM
Alias Names:NMO-IgG / AQP / AQP4 / Aquaporin (-4) / Devic's Antibody / Optic Neuritix Antibody / Optic-Spinal MS Antibody / Transverse Myelitis Antibody / Vision Loss Antibody
Methodology:Indirect Immunofluorescence Assay (IFA)
Edit Date:10/8/2009
Performed:Monday-Friday
Released:5-7 days after setup at PeaceHealth Laboratories' reference lab
CPT Code:86255-90
Specimen Collection Details
Collection:One 7.5 mL serum separator tube (SST).
Handling:Allow to clot, centrifuge and separate serum from cells and pour into a plastic vial. Refrigerate.
Stability:72 hours ambient, 14 days refrigerated.
Standard Volume:2 mL serum
Minimum Volume:200 µL serum
Transport:Refrigerated.
Comments:Useful in establishing the diagnosis of neuromyelitis optica (NMO) and related disorders (e.g., relapsing transverse myelitis or relapsing optic neuritis) and distinguishing these disorders from multiple sclerosis early in the course of disease. This allows initiation and maintenance of optimal therapy.
Interpretation Date:
A positive value is consistent with NMO or a related disorder, and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time.

Our prospective studies have revealed that 40% of adult patients with longitudinally-extensive transverse myelitis are seropositive and, of that group, 60% relapse or progress to NMO within 2 years. No seronegative patient relapsed in up to 7 years of follow-up.

Seronegativity does not exclude the diagnosis of NMO (current seronegativity rate is 27%).

Immunosuppressive therapy may result in seronegativity.

High levels of nonorgan-specific autoantibodies (which are frequent in patients with NMO) may preclude interpretation of a positive immunofluorescence pattern.